Join our daily newsletter At The Bell to receive exclusive market insights
- Archer Materials (AXE) has commenced building its lab-on-chip biosensing device, A1 Biochip, which could potentially be capable of simplifying disease detection
- Archer is working with a German biotech company to explore the on-chip conversion of in-demand commercial diagnostic
- The A1 Biochip is being built in a world-class semiconductor chip prototyping foundry in Sydney
- Archer will be designing and building its own biochip which will speed up the commercialisation of the biochip
- On the market this morning, Archer is up 4.40 per cent and is trading for 47.5 cents per share
Archer Materials (AXE) has started building its lab-on-chip biosensing device, A1 Biochip, which could potentially be capable of simplifying disease detection.
The materials technology company has made a step-change in advancing its graphene-based biosensor technology to start developing A1 Biochip.
Archer will be designing and building its own biochip, which means the company no longer needs prototyping sensor materials, graphene inks, 2D/3D printing, or circuit boards.
Developing the biochip product will speed up the commercialisation of the biochip.
“It is a global challenge to develop innovative biodevices that make the complex detection of disease safer and more reliable,” CEO Dr Mohammad Choucair said.
“Archer’s A1 Biochip technology aims to simplify disease detection at the point of care to potentially address an emerging multibillion-dollar industry,” he added.
The development will be led by nanotechnologist Dr Rebecca Soffee.
Archer has also started building its biochip in the Foundry alongside its CQ quantum computing chip development.
“Archer’s biochip development involves miniaturising medical lab tests onto an integrated circuit, a single chip, that is only a few millimetres in size,” Mohammad said.
“This is incredibly difficult, and there are very few people the world that can do this type of work, however, Dr Soffe has already made exciting advances on this front in only a few weeks since joining Archer,” he added.
On the market this morning, Archer is up 4.40 per cent and is trading for 47.5 cents per share at 11:51 am AEDT.
